Brand rules in.
Consistent outputs out.

Multi-kinase inhibition with VANTAGE-demonstrated PFS, balanced by AE burden.

VANATAR is a multi-kinase inhibitor with activity against VEGFR2, FGFR1, and RET (L-C03), contributing to its observed PFS benefit in VANTAGE (median 5.8 vs 3.9 months, HR 0.68; L-C02), though the clinical significance of PFS as a surrogate endpoint warrants consideration. The safety profile in Child-Pugh A patients was manageable (L-C04), yet hand-foot syndrome, hypertension, and diarrhea were common (L-C06) and required dose modifications from the standard 400mg daily (L-C05). Formulary decision-making should weigh the modest PFS gain against AE management resources and the lack of head-to-head data with other second-line TKIs.

Managing adverse events in sorafenib-experienced HCC patients on VANATAR.

In VANTAGE, VANATAR demonstrated a manageable safety profile in Child-Pugh A patients with advanced HCC previously treated with sorafenib (L-C04). The most common adverse events were hand-foot syndrome, hypertension, and diarrhea (L-C06). While median PFS extended to 5.8 months versus 3.9 months (HR 0.68, p=0.0021) (L-C02), clinicians should consider dose modifications and supportive care strategies in community practice. Recommended starting dose is 400mg once daily (L-C05).

#HCC #adverse #events #hand-foot

VANTAGE enrolled Child-Pugh A patients; data should not be extrapolated beyond.

The VANTAGE trial enrolled Child-Pugh A patients only [L-C04]. Safety and efficacy data have not been established in Child-Pugh B or C. Clinical decisions outside this population should rely on individual prescriber judgement and the prescribing information.

Hand-foot syndrome and hypertension were the most common adverse events.

The most common AEs in VANTAGE were hand-foot syndrome, hypertension, and diarrhea. Most were Grade 1-2 and managed with dose modification or supportive care. Dose interruption was required in approximately a third of patients.

VANATAR is administered as 400mg PO once daily [L-C05].

Recommended dosing is 400mg PO once daily, with or without food. Dose modification (300mg or 200mg) is permitted for grade 3 toxicity per the prescribing information. Hepatic monitoring is recommended at baseline and at periodic intervals.

Multi-kinase inhibition with VANTAGE-demonstrated PFS, balanced by AE burden.

VANATAR is a multi-kinase inhibitor with activity against VEGFR2, FGFR1, and RET (L-C03), contributing to its observed PFS benefit in VANTAGE (median 5.8 vs 3.9 months, HR 0.68; L-C02), though the clinical significance of PFS as a surrogate endpoint warrants consideration. The safety profile in Child-Pugh A patients was manageable (L-C04), yet hand-foot syndrome, hypertension, and diarrhea were common (L-C06) and required dose modifications from the standard 400mg daily (L-C05). Formulary decision-making should weigh the modest PFS gain against AE management resources and the lack of head-to-head data with other second-line TKIs.

Managing adverse events in sorafenib-experienced HCC patients on VANATAR.

In VANTAGE, VANATAR demonstrated a manageable safety profile in Child-Pugh A patients with advanced HCC previously treated with sorafenib (L-C04). The most common adverse events were hand-foot syndrome, hypertension, and diarrhea (L-C06). While median PFS extended to 5.8 months versus 3.9 months (HR 0.68, p=0.0021) (L-C02), clinicians should consider dose modifications and supportive care strategies in community practice. Recommended starting dose is 400mg once daily (L-C05).

#HCC #adverse #events #hand-foot

Cost-of-care comparisons require real-world evidence beyond VANTAGE.

Cost-of-care projections for VANATAR cannot be derived from VANTAGE alone — registrational trials don't reflect real-world utilization patterns. Post-market real-world evidence is required for total-cost-of-care modeling. The prescribing information and current formulary pricing are the starting point.